ITGR Integer Holdings Corporation
USHealthcareAs of 2026-07-10 16:00
Why ITGR matters now
Integer Holdings Corporation (ITGR) is a US stock in Healthcare. The latest InvestLog snapshot shows $93.68 with +1.88% on the session and $3.18B in market capitalization; recent performance reads 1-month +0.57% and YTD +15.98%.
The latest financial table shown here is Q1 2026, with revenue of $439.6M, net income of $16.5M, and EPS of $0.48. Investors can compare that operating picture with valuation signals such as P/E 29.01 and FCF yield 3.2%.
The latest indexable market news headline is "Integer Announces Conference Call to Discuss Second Quarter 2026 Results" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $108.00; recent insider activity includes Spence Donald J filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
29.01
PEG
—
P/B
1.84
P/S
1.67
EV/EBITDA
13.42
DCF Value
$133.81
FCF Yield
3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
23.3%
Operating Margin
10.4%
Net Margin
7.7%
ROE
8.2%
ROA
4.2%
ROIC
5.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $439.6M | $16.5M | $0.48 |
| Q4 2025 | $470.9M | $48.6M | $1.38 |
| FY 2025 | $1.85B | $102.8M | $2.89 |
| Q3 2025 | $466.6M | $39.7M | $1.11 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$108.00
Target (Median)
$108.00
Target Range
$101.00 - $115.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.65
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.